Familial partial lipodystrophy
(Redirected from FPLD)
Familial partial lipodystrophy (FPL) is a rare genetic disorder characterized by the selective loss of subcutaneous fat from various parts of the body. This condition is inherited in an autosomal dominant manner, meaning one copy of the altered gene in each cell is sufficient to cause the disorder.
Symptoms[edit | edit source]
The symptoms of familial partial lipodystrophy typically become noticeable during puberty. Affected individuals often have a lack of fatty tissue in the arms, legs, and trunk, and may have excessive fat deposits in the face and neck. Other symptoms may include insulin resistance, hypertriglyceridemia, hypertension, and diabetes mellitus.
Causes[edit | edit source]
Familial partial lipodystrophy is caused by mutations in the LMNA or PPARG genes. These genes provide instructions for making proteins that are involved in the regulation of fat cell differentiation and growth.
Diagnosis[edit | edit source]
Diagnosis of familial partial lipodystrophy is based on the clinical symptoms, family history, and genetic testing. Genetic testing can confirm the diagnosis and identify the specific gene mutation.
Treatment[edit | edit source]
Treatment for familial partial lipodystrophy is focused on managing the symptoms and preventing complications. This may include lifestyle modifications, medication to control diabetes and high cholesterol, and in some cases, plastic surgery to improve appearance.
See also[edit | edit source]
References[edit | edit source]
Familial partial lipodystrophy Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD